Rationale: Vascular smooth muscle cell (VSMC) proliferation and migration are crucial events involved in the pathophysiology of vascular diseases. Sirtuin 1 (SIRT1), a class III histone deacetylase (HDAC), has been reported to have the function of antiatherosclerosis, but its role in neointima formation remains unknown.
T he process of neointima formation is common to various forms of vascular diseases such as atherosclerosis, instent restenosis, vein bypass graft failure, and transplant vasculopathy. 1, 2 In response to vascular injury, the activated medial smooth muscle cells (SMCs) proliferate and migrate into the intima, where they proliferate and subsequently produce an abundant extracellular matrix (ECM) to form the neointima. 2, 3 Although recent studies have shed light on some of the pathophysiological mechanisms that are involved in vascular smooth muscle cell (VSMC) proliferation and migration, the molecular modulators that link these coordinated responses of VSMCs to injury remain to be elucidated.
Sirtuin 1 (SIRT1), the closest homology to the yeast Sir2 protein (silent information regulator 2) in human sirtuins, 4 has been implicated in aging, metabolism, and tolerance to oxidative stress via its ability to deacetylate a variety of substrates, including histones, transcription factors, and coregulators. 5 SIRT1 also serves as a key regulator in vascular endothelial homeostasis by controlling angiogenesis, vascular tone, and endothelial dysfunction as well as by decreasing atherosclerosis. 6, 7 Growing evidence has shown that SIRT1 is involved in multiple disease-relevant pathways such as cellcycle regulation, cell apoptosis, and migration. 8 -10 A smallmolecule activator of SIRT1, resveratrol, which is abundant in grape skin and red wine, has been shown to block neointima formation after arterial injury 11 and to exert beneficial effects on vascular diseases such as atherosclerosis and hypertension. 12, 13 We therefore hypothesized that SIRT1 may play a critical role in the development of vascular diseases, which are characterized by neointima formation.
To determine the role of SIRT1 in the regulation of neointima formation, we performed both ligation and wire injury of the carotid arteries in SMC-SIRT1 transgenic (Tg) and wild-type (WT) mice. Here, we report direct evidence that SIRT1 in VSMC acts as a modulator in neointima formation, and suppression of both VSMC proliferation and migration by SIRT1 results in reduced neointima formation.
Methods
An expanded Materials and Methods section is available in the online Data Supplement available at http://circres.ahajournals.org.
Generation of SMC-SIRT1 Transgenic Mice
All of the animal protocols were approved by the Animal Care and Use Committee at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC). The transgenic mouse lines were produced in a C57BL/6 background via the microinjection of human SIRT1 cDNA under the control of a minimal SM22␣ promoter.
Carotid Artery Ligation and Carotid Artery Wire Injury Model
Nine-to 12-week-old male SMC-SIRT1 Tg mice and their littermate WT controls underwent complete carotid artery ligation 14 or carotid artery wire injury 15 as described previously.
Histological and Morphometric Analysis
Carotid arteries were harvested at the indicated times after injury. The cross-sectional areas of the intima and media were measured in H&E-stained sections in a blinded manner by a single observer using Image Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD). Neointima formation was determined as the ratio of the intimal area to medial area (I/M). The immunohistochemical analyses were processed according to standard procedures.
Cell Culture, Adenovirus Generation, and Infection
Rat aortic SMCs were isolated from the thoracic aorta of male Sprague-Dawley rats by enzymatic digestion and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). The replication-defective adenoviral vectors expressing SIRT1 (Ad-SIRT1) or control green fluorescent protein (Ad-GFP) and adenovirus-mediated knockdown of SIRT1 (Ad-SIRT1 RNAi) or control vector (Ad-U6) were generated using the AdEasy Vector kit (Quantum Biotechnologies, Randburg, South Africa) as described previously. 7, 16 VSMCs were infected for 12 or 24 hours with the above adenovirus using a multiplicity of infection (MOI) of 100, washed and incubated in serum-free medium without virus for at least 24 hours.
[ 3 H]Thymidine Incorporation, Flow Cytometry Analysis and Migration Assay
The VSMC proliferation capacity was analyzed by [ 3 H]thymidine incorporation and flow cytometry analysis, and the VSMC migratory capacity was measured by a scraping injury and transwell assay. Details are provided in the online Data Supplement.
Southern Blotting, RT-PCR, Western Blotting, and Luciferase Reporter Assay
Target gene expression levels were probed either by reverse transcription-polymerase chain reaction (RT-PCR) using the corresponding primers (online Table II ) or by Western blot analysis. The indicated reporter constructs (0.2 g) were cotransfected with the indicated expression vectors and the internal control thymidine kinase promoter-Renilla luciferase reporter plasmid (pRL-TK; 30 ng, Promega, Fitchburg, WI) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Luciferase activity was assessed using the Dual-Luciferase Reporter Assay System (Promega).
Statistical Analysis
Data analysis was performed by using SPSS version 13.0 (SPSS, Inc., Chicago, IL). Data are presented as the meansϮSEM. Paired data were compared by Student t tests. Differences among groups were determined with 1-way or 2-way analysis of variance (ANOVA) with repeated measures, followed by Bonferroni post hoc test. A probability value of Ͻ0.05 was considered significant.
Results

SIRT1 Expression Is Downregulated by Vascular Injury
To investigate the role of SIRT1 in VSMC function and neointima formation, we performed a mouse left common 14 and then examined the expression of SIRT1 after injury. The Western blot analyses showed that SIRT1 expression was significantly decreased during neointima formation at 7, 14, and 28 days after injury ( Figure 1 ). This finding suggests that SIRT1 may be involved in the development of neointimal lesions.
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Generation of SMC-Specific SIRT1 Tg Mice
To study the role of SIRT1 in the regulation of neointima formation, particularly in VSMCs, we generated SMC-SIRT1 Tg mice in a C57BL/6 background. The transgenic construct contained human SIRT1 cDNA under the control of a VSMCspecific mouse minimal SM22␣ promoter ( Figure 2A ). 17 Two independent strains of SMC-SIRT1 Tg mice were identified by Southern blot analysis ( Figure 2B ), and the transgene inheritance followed a Mendelian segregation pattern. No significant differ-ences in heart function (analyzed by echocardiography) or basal systolic blood pressures were observed between the WT and SMC-SIRT1 Tg mice (online Table I ). Genomic Southern blot analyses indicated that 2 transgenic strains carried similar copy numbers of the transgene. Human SIRT1 mRNA and protein were detected in the arteries of SMC-SIRT1 Tg mice ( Figure 2C and 2D). Moreover, as expected, increased immunostaining of SIRT1 was observed in the media of carotid arteries in SMC-SIRT1 Tg mice ( Figure 2E ).
SIRT1 Represses Neointima Formation in Response to Carotid Ligation and Carotid Artery Wire Injury
To determine whether SIRT1 modulates neointima formation, we examined the effect of both carotid ligation and carotid artery wire injury in transgenic and littermate WT mice. Four weeks after carotid ligation, the luminal area of carotid arteries was significantly reduced. Most of the cells in the neointima were VSMCs (SM␣-actin staining; data not shown). At day 14 after ligation, a decreased tendency of I/M ratio in SMC-SIRT1 Tg mice was observed. At 28 days after ligation, I/M ratio was significantly reduced in SMC-SIRT1 Tg mice than in WT mice ( Figure 3A ). Consistent with these findings, at 14 days after the carotid artery wire injury, I/M ratio was significantly suppressed in SMC-SIRT1 Tg mice than in WT mice (online Figure I, A) .
Proliferating cell nuclear antigen (PCNA)-staining analyses were performed to determine the level of cellular proliferation in the neointima. Staining for PCNA and intimal PCNA-positive cells were significantly reduced in SMC-SIRT1 Tg mice than in WT mice in each of the 2 mouse models of vascular injury ( Figure 3B , online Figure I, B ). However, no change in apoptosis was observed between WT and SMC-SIRT1 Tg mice in carotid arteries after ligation (online Figure II ).
SIRT1 Inhibits VSMC Proliferation and Migration In Vitro
Because VSMC proliferation and migration are 2 key events in neointima formation following vascular injury, we investigated whether SIRT1 inhibits VSMC proliferation in vitro. The overexpression of SIRT1 in VSMCs resulted in a significant reduction of cell proliferation, as determined by [ 3 H] thymidine incorporation following serum induction ( Figure 4A ). Furthermore, FACS analyses of both VSMCs and A7r5 cells with SIRT1 overexpression revealed a significant accumulation of the cells in G0/G1 phase ( Figure 4B , online Figure III) . These findings suggest that SIRT1 inhibits VSMC proliferation by blocking cell-cycle entry into S phase. Next, we examined the potential role of SIRT1 in VSMC migration using TNF-␣ as a chemoattractant. Wound healing assays indicated that the overexpression of SIRT1 resulted in a significant inhibition of VSMC migration ( Figure 4C ). Boyden chamber migration assays further confirmed the inhibitory effect of SIRT1 overexpression on VSMC migration ( Figure 4E ). In contrast, an RNAi-mediated SIRT1 knockdown resulted in a significant increase in VSMC migration ( Figure 4D and 4F).
SIRT1 Inhibits the Expression of Cyclin D1 and MMP-9 in VSMCs
Because cyclin D1 and matrix metalloproteinase-9 (MMP-9) are 2 key regulators in VSMC proliferation and migration, 18, 19 we investigated whether cyclin D1 and MMP-9 were involved in the inhibitory effect of SIRT1 on VSMC proliferation and migration. Western blot analyses of cyclin D1 and MMP-9 protein levels showed that the overexpression of SIRT1 significantly decreased cyclin D1 and MMP-9 expression in VSMCs ( Figure 5A and 5C) , and a similar finding of reduced cyclin D1 expression was observed in the SMC cell line A10 (online Figure IV) . SIRT1 knockdown by RNAi produced an opposite effect ( Figure 5B and 5D ). In addition, we found that overexpression of SIRT1 reduced cyclin E and CDK2 expression (online Figure V, A) , although SIRT1 knockdown by RNAi did not affect cyclin E and CDK2 expression (online Figure V, B) .
Using gelatin zymography, we assayed the enzymatic activity of secreted MMP-9. As shown in Figure 5E , SIRT1 overexpression significantly inhibited the enzymatic activity of MMP-9. Consistent with these results, VSMC treatment with sirtinol (a chemical inhibitor of SIRT1) plus TNF-␣, increased MMP-9 protein expression ( Figure 5F ). The overexpression of SIRT1 in VSMCs did not have significant effects on other VSMC migration-associated genes, including MMP-2, TIMP-1, TIMP-2, and MMP-3 (online Figure VI) . Collectively, these results indicate that MMP-9 plays an important role in the inhibitory effects of SIRT1 on VSMC migration.
Decreased Cyclin D1 and MMP-9 Expression/Activity in SMC-SIRT1 Tg Mice
To validate that cyclin D1 and MMP-9 function as downstream effectors of SIRT1 in the modulation of neointima formation in vivo, we analyzed cyclin D1 and MMP-9 expression in carotid arteries following ligation. Cyclin D1 expression was significantly decreased in the ligated arteries of SMC-SIRT1 Tg mice ( Figure 6A ). Furthermore, the increased MMP-9 expression observed after 1 day of ligation was significantly attenuated in SMC-SIRT1 Tg mice ( Figure 6B ). Zymography assays were performed using protein extracts from ligated and sham-operated carotid arteries of WT and SMC-SIRT1 Tg mice. The MMP-9 enzymatic activity in the ligated carotid arteries of SMC-SIRT1 Tg mice was significantly reduced in comparison with that detected in WT mice ( Figure 6C ). An immunostaining assay also revealed that the expression levels of cyclin D1 and MMP-9 were reduced in the ligated arteries of SMC-SIRT1 Tg mice in comparison with those in their WT littermates at the indicated time points ( Figure 6D ).
AP-1 Is Implicated in the Transcriptional Regulation of Cyclin D1 and MMP-9 by SIRT1
We next sought to determine whether SIRT1 regulated cyclin D1 and MMP-9 transcription. We found that SIRT1 overexpression significantly decreased cyclin D1 and MMP-9 mRNA levels that were induced by serum and TNF-␣, respectively ( Figure 7A ). Because transcription factor activa- tor protein-1 (AP-1) is important in the regulation of cyclin D1 and MMP-9 transcription, 20 -22 we performed a transient transfection analysis to determine whether AP-1 played a role in the transcriptional regulation of cyclin D1 and MMP-9 by SIRT1. Using 2 luciferase reporter vectors under the controls of the cyclin D1 (Ϫ903 to ϩ202) and MMP-9 (Ϫ711 to ϩ19) promoters, we found that c-Fos/c-Jun increased the promoter activity of both cyclin D1 and MMP-9, and the induction of the cyclin D1 and MMP-9 promoters by c-Fos/c-Jun was blocked by pcDNA3.1-SIRT1 ( Figure 7B ). Furthermore, point mutations or deletions of the AP-1 DNA-binding site significantly decreased the ability of SIRT1 to repress the cyclin D1 and MMP-9 promoters ( Figure 7C ).
To investigate whether endogenous SIRT1 regulates cyclin D1 and MMP-9 transcription by associating with the chromatin region that contains the AP-1 DNA binding site, we performed chromatin immunoprecipitation (ChIP) assays. As shown in Figure 8A and 8B, chromatin fragments containing the AP-1 DNA binding site from the cyclin D1 and MMP-9 promoter region were observed specifically in the immunoprecipitates obtained using the antimSirt1, antic-Fos, or c-Jun antibodies. Furthermore, a ChIP analysis demonstrated an enrichment of c-Fos and c-Jun at the cyclinD1 and MMP-9 promoters following RNAi knockdown of SIRT1 ( Figure 8C and 8D) . These results suggest that SIRT1 can be recruited to the cyclin D1 and MMP-9 promoter region by tethering c-Fos and c-Jun and that SIRT1 alters the occupancy of c-Fos and c-Jun at the cyclin D1 and MMP-9 promoters to regulate their expression.
We further determined whether SIRT1 affected c-Fos and c-Jun activity. The immunofluorescent staining results showed that SIRT1 and c-Fos/c-Jun colocalized in the cell nucleus (online Figure VII) , and the coimmunoprecipitation analyses revealed that SIRT1 and c-Fos/c-Jun interacted physically (online Figure VIII) . Because SIRT1 usually functions via the deacetylation of target proteins, transient transfection and immunoprecipitation analyses were performed to determine whether SIRT1 regulated the acetylation status of AP-1 in A10 cells. SIRT1 overexpression markedly reduced the acetylation level of both c-Fos and c-Jun under TNF-␣-inducing conditions (online Figure IX) .
Discussion
In the present study, we demonstrated for the first time that SIRT1 expression was decreased in the process of neointima formation and that overexpression of SIRT1 in VSMCs inhibited neointima formation following vascular injury in mice. Given that increased VSMC proliferation is one of the central features associated with the development of neointimal lesions, several molecules have been shown to regulate the formation of neointima by inhibiting VSMC proliferation. 1 The mouse carotid artery ligation model is a very suitable model for the study of SMC proliferation, and in some cases, it mimics the vascular lesions that develop in humans at sites of altered hemodynamics that are associated with low shear stress. 14, 23 Using this mouse model, we found that SIRT1 expression was substantially decreased with the development of the neointima, which indicated that SIRT1 was involved in this process and might act as For the sham group, the entire operation was performed excluding the ligation. C, Representative gelatin zymography assay for pooled samples of carotid artery from WT and SMC-SIRT1 Tg mice at 1 day after ligation or the sham operation in comparison with that for WT mice. Quantitative analyses of Western blot (normalized to that of ␤-actin, top panel). Values represent the meansϮSEM (nϭ3 with 3 mice in each pool). *PϽ0.001 versus ligated WT mice. D, Representative sections of injured mouse carotid arteries at 28 days or 1 day after ligation that were immunostained for cyclinD1 (ligation for 28 days, brown, left) or MMP-9 (ligation for 1 day, brown, right), respectively. Scale bar: 25 m. The internal elastic lamina is indicated by black arrows. a growth suppressor. This presumption was confirmed in both carotid artery ligation and carotid artery wire injury models by a reduction of the neointimal thickening in the injured artery of SMC-SIRT1 Tg mice. It was further strengthened by a remarkable reduction of in situ cell proliferation, as determined by the number of PCNApositive cells in the intima. Still, the mechanism by which SIRT1 expression is downregulated during neointima formation remains to be elucidated.
The mechanism responsible for the growth suppression induced by SIRT1 was found to be a cell-cycle arrest at the G1 phase and a reduction in DNA synthesis; these results were consistent with recent findings showing that the increased expression of SIRT1 causes a delay in S-phase entry and greatly reduces the growth of some specific cells. 8, 9, 24, 25 In contrast, the inhibition of SIRT1 by shRNAs in telomerase-immortalized human cells has been shown to enhance cell growth under normal and nutrient-limiting conditions, 26 and SIRT1-deficient mouse embryonic fibroblasts (MEFs) were also demonstrated an enhanced proliferative capacity under conditions of chronic, sublethal oxidative stress. 27 Nevertheless, a growth arrest effect, but not a growth-inducing effect, has been previously observed in human umbilical-vein endothelial cells (HUVECs) in which SIRT1 is inhibited by sirtinol or siRNA. 28 Similarly, we also observed a reduction of DNA synthesis in serum-induced VSMCs during the knockdown of endogenous SIRT1 by RNAi (online Figure X) , which suggests that endogenous SIRT1 is required for both growth and proliferation in some certain types of cells including VSMCs. During formation of the neointima, the processes of VSMC proliferation and migration are interrelated. After stimulation, most of the migrating VSMCs are in late G1 phase of the cell cycle. 29 A reduction in VSMC proliferation by SIRT1 overexpression may result in reduced VSMC migration. As we proposed, the results of our cell migration experiments demonstrated that SIRT1 overexpression resulted in a reduction of the VSMC migratory capacity. Thus, the reduced numbers of migratory VSMCs might be due to the effects of SIRT1 overexpression or caused indirectly by the decreased VSMC proliferation. Hence, the inhibitory effects of SIRT1 on VSMC proliferation and migration contributed to the reduced neointimal lesion observed in the injured vessels of SMC-SIRT1 Tg mice.
Cyclin D1 acts as a mitogenic signal sensor and promotes progression through the G1-S phase of the cell cycle. 30 Cyclin D1 overexpression is associated with human tumorigenesis and cellular metastases. 31 Increased cyclin D1 protein expression and medial VSMC growth have also been observed in rat ballooninjured carotid arteries. 32 In addition, DNA synthesis defects are apparent in MEFs and 3T3 cells derived from cyclin D1 Ϫ/Ϫ mice. 33 We found that SIRT1 overexpression inhibited VSMC proliferation and reduced cyclin D1 expression at both the mRNA and protein levels. The inhibitory effect of SIRT1 on cyclin D1 protein expression was also observed in injured arteries from SMC-SIRT1 Tg mice. MMP-9 has been reported to be a major regulator in VSMC proliferation and migration and in neointima formation. 34 Nonspecific MMP inhibition has also been proposed to oppose remodeling, as evidenced by an inhibition of outward arterial remodeling. 35 SIRT1 overexpression in VSMCs resulted in decreased MMP-9 mRNA and protein expression, enzymatic activity and VSMC migration following stimulation with TNF-␣. Moreover, ligated vessels from SMC-SIRT1 Tg mice displayed reduced MMP-9 protein levels, enzymatic activity, and immunoactivity. In addition, cyclin D1 has been reported to modulate the invasive capacity of cells by increasing MMP-9 activity and cell motility, 36 whereas MMP-9 Ϫ/Ϫ VSMCs display reduced proliferation and cyclin D1 protein levels. 37 Therefore, the inhibitory effects of SIRT1 on VSMC proliferation and migration may be caused by a downregualtion of these two effectors and their interactions. Although the effects of cyclin D1 and MMP-9 on VSMC proliferation and migration have been well documented, additional studies are needed to confirm that the effects of SIRT1 are mediated directly through cyclin D1 and MMP-9 in vivo. Considering that there are many other SIRT1 target proteins (such as survivin, 38 FOXO1, 39 and angiotensin II type I receptor (AT1R) 13 ) that play important roles in VSMC proliferation, neointimal hyperplasia, and hypertension, we also detected the expression of these proteins in ligated vessels from WT and SMC-SIRT1 Tg mice (online Figure XI) . It will be interesting to further elucidate the involvement of these proteins in the regulation of neointima formation by SIRT1.
Numerous studies have demonstrated that AP-1, a transcription factor that consists of a homodimer and heterodimers of Jun family members and heterodimers of the Fos and Jun families, is crucial for the mediation of VSMC proliferation and neointima formation in response to vascular injury. 40 The activity of AP-1 is regulated by posttranslational modifications, including extensively studied phosphorylation and less-studied acetylation modifications. [41] [42] [43] An increase in c-Fos and c-Jun gene expression and enhanced AP-1 DNA-binding activity activated by MAP kinases have been observed during neointima development following arterial injury, 44 and the decoy oligodeoxynucleotide (ODN) of AP-1 has been shown to abolish neointima formation after balloon injury. 40, 45 Recently, our group and others have shown that SIRT1 can interact with AP-1, 16, 46, 47 and then inhibit its transcriptional activation. However, little information is available concerning the effect of AP-1 acetylation on the function of VSMCs. In the present study, we found that endogenous SIRT1, c-Fos, and c-Jun bound to the AP-1 binding site of the cyclin D1 and MMP-9 promoters, and that SIRT1 inhibition resulted in an enrichment of c-Fos and c-Jun at the promoters of cyclin D1 and MMP-9, respectively. Moreover, SIRT1 interacted and colocalized with both c-Fos and c-Jun. SIRT1 overexpression markedly reduced the acetylation level of both c-Fos and c-Jun induced by TNF-␣, which suggested that the repressive effect of SIRT1 on AP-1 activity and downstream events was due to its deacetylase activity in VSMCs, although the in vivo effects of SIRT1 on AP-1 acetylation remain to be verified. Taken together, our findings suggest that the decreased VSMC proliferation and migration and the reduced neointima formation are, at least in part, due to a decrease in the transcriptional activity of AP-1 and a downregulation of cyclin D1 and MMP-9 expression.
In summary, our findings demonstrate that SIRT1 is a novel modulator that is involved in the process of neointima formation and further elucidate that the repression of AP-1 activity by SIRT1 contributes to the decreased expression of cyclin D1 and MMP-9. These effects, in turn, lead to a decrease in VSMC proliferation and migration and reduced neointima formation. The present findings indicate that SIRT1 may be an attractive therapeutic target for the prevention of vascular diseases.
